Hemogenyx Operating Income vs Net Income From Continuing Ops Analysis
HEMO Stock | 343.40 20.90 6.48% |
Hemogenyx Pharmaceuticals financial indicator trend analysis is much more than just examining Hemogenyx Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemogenyx Pharmaceuticals is a good investment. Please check the relationship between Hemogenyx Pharmaceuticals Operating Income and its Net Income From Continuing Ops accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Operating Income vs Net Income From Continuing Ops
Operating Income vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemogenyx Pharmaceuticals Operating Income account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have strong relationship.
The correlation between Hemogenyx Pharmaceuticals' Operating Income and Net Income From Continuing Ops is 0.64. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Hemogenyx Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Hemogenyx Pharmaceuticals' Operating Income and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Hemogenyx Pharmaceuticals PLC are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Operating Income i.e., Hemogenyx Pharmaceuticals' Operating Income and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Operating Income
Operating Income is the amount of profit realized from Hemogenyx Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Hemogenyx Pharmaceuticals PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Net Income From Continuing Ops
Most indicators from Hemogenyx Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to gain to about 5.2 M in 2024. Issuance Of Capital Stock is likely to gain to about 5.3 M in 2024
Hemogenyx Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Hemogenyx Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemogenyx Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.0M | 2.7M | 8.5M | 7.1M | 6.1M | 3.5M | |
Total Stockholder Equity | (346.5K) | 890.8K | 8.2M | 3.3M | 2.8M | 2.1M | |
Net Debt | 758.6K | (184.2K) | (6.8M) | 890.1K | 1.7M | 1.8M | |
Retained Earnings | (6.0M) | (8.0M) | (13.1M) | (17.1M) | (23.8M) | (22.6M) | |
Cash | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Cash And Short Term Investments | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Common Stock Total Equity | 3.6M | 3.6M | 3.6M | 4.3M | 5.0M | 2.9M | |
Common Stock Shares Outstanding | 360.7M | 414.8M | 774.0M | 979.7M | 1.1B | 1.2B | |
Liabilities And Stockholders Equity | 1.0M | 2.7M | 8.5M | 7.1M | 6.1M | 3.5M | |
Other Current Assets | 55.8K | 105.0K | 298.2K | 62.0K | 922.0K | 968.1K | |
Total Current Assets | 554.5K | 1.9M | 7.1M | 2.6M | 2.2M | 2.1M | |
Common Stock | 3.6M | 3.6M | 4.3M | 9.8M | 11.8M | 12.3M | |
Short Long Term Debt Total | 1.3M | 1.6M | 10.2K | 3.4M | 2.9M | 1.5M | |
Other Current Liab | 80.3K | 47.5K | 46.9K | 51.9K | 77.3K | 71.2K | |
Total Current Liabilities | 181.6K | 1.8M | 352.8K | 748.4K | 652.1K | 526.2K | |
Net Tangible Assets | 686.4K | (608.6K) | 635.9K | 7.8M | 8.9M | 9.4M | |
Accounts Payable | 61.4K | 113.2K | 295.8K | 374.3K | 301.7K | 154.9K | |
Non Current Assets Total | 495.4K | 747.3K | 1.4M | 4.5M | 3.9M | 4.1M | |
Non Current Liabilities Total | 1.2M | 10.0K | 306.0K | 3.1M | 2.7M | 2.8M | |
Other Stockholder Equity | 7.7M | 10.0M | 23.0M | 16.8M | 14.9M | 10.1M | |
Total Liab | 1.4M | 1.8M | 352.8K | 3.8M | 3.3M | 3.5M | |
Accumulated Other Comprehensive Income | 452.5K | 756.9K | 878.3K | (58.8K) | 1.1M | 1.1M | |
Intangible Assets | 272.8K | 262.1K | 255.0K | 441.5K | 470.2K | 356.6K | |
Property Plant And Equipment Net | 233.4K | 268.7K | 797.1K | 3.9M | 3.3M | 3.5M | |
Non Currrent Assets Other | 0.0 | 223.6K | 142.6K | 140.8K | 153.7K | 155.6K | |
Net Receivables | 32.3K | 56.3K | 7.5K | 9.8K | 5.1K | 4.9K | |
Property Plant Equipment | 173.9K | 233.4K | 268.7K | 797.1K | 916.7K | 962.5K | |
Net Invested Capital | 797.6K | 2.5M | 8.2M | 3.3M | 2.8M | 3.4M | |
Property Plant And Equipment Gross | 233.4K | 268.7K | 1.1M | 4.5M | 4.0M | 4.2M | |
Net Working Capital | 372.9K | 138.4K | 6.8M | 1.8M | 1.5M | 2.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.